Olfactory neuroblastoma: A case report

Uslu, Gonca Hanedan; Canyılmaz, Emine; Zengin, Ahmet; Munğan, Sevdegül; Yöney, Adnan; Bahadir, Osman; Gocmez, Huseyin

doi:10.3892/ol.2015.3821

Cited by 6 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multimodality therapy, including chemotherapy, has been suggested by a number of studies (13)(14)(15)(16). In addition, recent study by Uslu et al (17) reported the case of a 69-year-old patient with olfactory neuroblastoma who was treated by combined surgical excision and radiotherapy. Currently, treatment with radionuclides bound to somatostatin analogues is performed in selected patients with neuroendocrine tumors, with considerable response.…”

Section: Introductionmentioning

confidence: 98%

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

Sabongi

Gonçalves

Alves

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant tumor that accounts for 3% of all tumors of the nasal cavity. The incidence of ENB is 0.4 cases per million in the general population, and the most common symptoms are nasal obstruction and epistaxis. Previous studies have indicated the presence of somatostatin receptors in this tumor type. Common treatment strategies for ENB include resection and adjuvant radiotherapy and/or chemotherapy (combined treatment); however, the rate of recurrence is high. Treatment of neuroendocrine tumors using radionuclides bound to somatostatin analogues is well established in clinical practice. However, a standard and effective therapeutic approach has not been reported for ENB. The current study described the case of a 74-year-old female with numerous recurrences of ENB following multiple treatments and without possibility of resection. The patient was treated with the radiolabeled-somatostatin analogue, 177 Lutetium-DOTA-octreotate ( 177 Lu-DOTA-TATE), which successfully controlled the disease. This suggests that 177 Lu-DOTA-TATE is a potential treatment for ENB and may represent an effective alternative and novel therapeutic strategy for this disease.

show abstract

Section: Introductionmentioning

confidence: 98%

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

Sabongi

Gonçalves

Alves

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…[6][7][8][9] A nasal mass was often identified on nasoendoscopic examination in patients who presented with olfactory neuroblastoma. 6,[10][11][12][13][14] Olfactory neuroblastomas also have a bimodal age distribution, peaking in the second and sixth decades of life. 4 Our study population age has a mode in the fifth decade, which does not coincide with this bimodal age distribution.…”

Section: Discussionmentioning

confidence: 99%

Magnetic resonance imaging findings in patients with idiopathic olfactory dysfunction and normal findings on nasoendoscopy

2022

View full text Add to dashboard Cite

Objective In presentations of anosmia or dysosmia, magnetic resonance imaging may be required to screen for intracranial pathology such as olfactory neuroblastomas and other intracranial masses impacting on the olfactory pathway. This study aimed to establish positive magnetic resonance imaging findings of anosmia or dysosmia for scans performed before the coronavirus disease 2019 pandemic. Methods The study examined the outcome of patients who presented with isolated olfactory dysfunction and who underwent magnetic resonance imaging between 2015 and 2019. Results Of the 131 patients, 41 (31.3 per cent) had normal scan findings, 50 (38.2 per cent) had insignificant paranasal mucosal disease and 6 (4.6 per cent) had mucosal thickening significant enough to require additional intervention. These interventions included repeat nasoendoscopy or commencement of intranasal or oral steroids. No patients had olfactory neuroblastoma. Conclusion Only 4.6 per cent of the magnetic resonance imaging scans revealed abnormal findings related to anosmia or dysosmia, and none required ENT surgical intervention. None of the magnetic resonance imaging scans identified an olfactory neuroblastoma or intracranial masses impacting on the olfactory pathway.

show abstract

“…ONB may histologically mimic a number of types of tumor within the sinonasal tract, making it much difficult to diagnosis [ 5 ]. Multi-modality imaging is essential to correctly assess the extent of the disease in the management of this infrequent tumor [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

Olfactory Neuroblastoma of the Sinonasal Tract with Prominent Orbital Protrusion: A Case Report and Literature Review

Chen

Jing-Xin

Yang

et al. 2021

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Olfactory neuroblastoma (ONB) is a rare malignant neuroectodermal tumor of the nasal cavity. Olfactory neuroblastoma centered in the posterior right orbit with prominent orbital protrusion is even rare. Grading ONB is extremely important as individualized treatment plans must be formulated according to tumor grade. We report the case of a 67-year-old female who presented with the chief complaints of persistent nasal congestion with intermittent epistaxis and unilateral proptosis over the past five years. Radiological imaging was suggestive of a large heterogeneous mass in the right superior nasal cavity with extensions into the right medial orbit, nasopharynx, the right maxillary sinus, the anterior cranial fossa, right ethmoidal, frontal and bilateral sphenoidal sinuses, as well as into the right frontal lobe. Assessment of the radiologic features revealed the diagnostic possibility of olfactory neuroblastoma. A nasopharyngeal biopsy confirmed an olfactory neuroblastoma. Frontal osteoplastic craniotomy and excision of the intracranial part of the tumor from above and transnasal endoscopic removal of the mass in the nasal cavities, paranasal sinuses and right medial orbit from below was done. Evaluation of histopathological characteristics and immunohistochemical findings revealed a diagnosis of WHO grade IV olfactory neuroblastoma. Because of poor economic condition, the patient did not take adjuvant radiotherapy and chemoradiation and post-operative examination. We report a huge ONB centered in the posterior right orbit with prominent orbital protrusion. Magnetic resonance image and computed tomography are helpful for evaluating the appearance and the extent of ONB, as well as grading this tumor, which may aid therapeutic decisions and improve survival.

show abstract

Olfactory neuroblastoma: A case report

Cited by 6 publications

References 12 publications

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report

Magnetic resonance imaging findings in patients with idiopathic olfactory dysfunction and normal findings on nasoendoscopy

Olfactory Neuroblastoma of the Sinonasal Tract with Prominent Orbital Protrusion: A Case Report and Literature Review

Contact Info

Product

Resources

About